Voriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity
Frontiers in Pharmacology · 10.07.2026 · 17
DOI: 10.3389/fphar.2026.1839608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.07.2026. Verfasst von Lin Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To analyze the incidence, types, and risk factors of adverse drug reactions (ADRs) associated with voriconazole (VRC).
Methods
A prospective observational study was conducted at the First Hospital of Changsha from March 1, 2024, to December 31, 2025. Multivariate logistic regression analyses and receiver operating characteristic (ROC) curve analysis were performed to identify risk factors of ADRs.
Results
A total of 370 patients were included in the analysis. ADRs occurred in 70 patients (18.9%), while 300 patients (81.1%) experienced no ADRs. The most common ADRs were hepatotoxicity (39/370, 10.5%), neurological disorders (20/370, 5.4%), and visual symptoms (18/370, 4.9%). Most ADRs developed within 4–7 days after treatment initiation (53.6%). Notably, 59 patients (84.3%) discontinued VRC due to ADRs. Among patients with hepatotoxicity, the median trough concentration ( C trough ) was 4.40 mg/L (range, 1.43–10.01 mg/L), which was significantly higher than that in the non-ADR group (3.29 mg/L; range, 0.64–12.80 mg/L; P = 0.016). No significant association was found between VRC C trough and either neurological disorders or visual symptoms. However, patients who experienced visual symptoms received a significantly higher VRC dose (8.00 mg/kg/day; range, 5.00–12.00 mg/kg/day) compared with those without visual symptoms (7.02 mg/kg/day; range, 1.19–13.33 mg/kg/day) ( P = 0.029). Multivariate logistic regression analysis identified VRC C trough and albumin–bilirubin (ALBI) score as significant predictors of hepatotoxicity ( P = 0.033 and P = 0.036, respectively). ROC analysis further indicated that patients with an ALBI score > −2.095 were at increased risk of developing hepatotoxicity.
Conclusion
Early monitoring of VRC C trough is essential. In addition to trough levels, the ALBI score demonstrated good predictive value for hepatotoxicity and may represent a promising new approach for predicting hepatotoxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
- Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China.
Zitieren
APA
Hu, L., Su, Y., Tang, X., Li, Y., & Hou, J. (2026). Voriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1839608
Vancouver
Hu L, Su Y, Tang X, Li Y, Hou J. Voriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1839608
BibTeX
@article{Hu2026,
author = {Hu, Lin and Su, Yuan and Tang, Xi and Li, Yanfei and Hou, Ju},
title = {Voriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1839608}
}
EUVIMED